par Aftimos, Philippe ;Awada, Ahmad
Référence Advances in therapy, 28, 11, page (973-985)
Publication Publié, 2011-11
Article révisé par les pairs
Titre:
  • Survival benefit of eribulin mesylate in heavily pretreated metastatic breast cancer: what next?
Auteur:Aftimos, Philippe; Awada, Ahmad
Informations sur la publication:Advances in therapy, 28, 11, page (973-985)
Statut de publication:Publié, 2011-11
Sujet CREF:Cancérologie
Mots-clés:anthracyclines
capecitabine
clinical trials
eribulin mesylate
metastatic breast cancer
microtubules
taxanes
MeSH keywords:Adult
Aged
Antineoplastic Agents -- administration & dosage -- adverse effects -- pharmacology
Breast -- pathology
Breast Neoplasms -- drug therapy -- pathology
Clinical Trials as Topic
Drug Monitoring -- methods
Ethers, Cyclic -- chemistry
Female
Furans -- administration & dosage -- adverse effects -- pharmacology
Humans
Ketones -- administration & dosage -- adverse effects -- pharmacology
Microtubules -- drug effects
Neoplasm Metastasis
Neutropenia -- chemically induced
Treatment Outcome
Note générale:Journal Article
Review
SCOPUS: re.j
Langue:Anglais
Identificateurs:urn:issn:0741-238X
info:doi/10.1007/s12325-011-0070-9
info:scp/82355191648
info:pmid/22020735